Evidence map›Paper›PMID 39591989›Full record

ArticleOpen biology2024

Aurodox inhibits type III secretion in multiple Gram-negative pathogens.

David R Mark, Nicky O'Boyle, Kabo R Wale, Samantha K Tucker, Rebecca E McHugh, Andrew J Roe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Mesolens imaging in microbiology.Essays in biochemistry · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

David R MarkSchool of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK.
Nicky O'BoyleDepartment of Pathology, School of Microbiology & School of Medicine, University College Cork, National University of Ireland, Cork T12 K8AF, Ireland.
Kabo R WaleSchool of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK.
Samantha K TuckerSchool of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK.
Rebecca E McHughSchool of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK.
Andrew J RoeSchool of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0003-3698-6134

Funding

CICThe Medical Research CouncilWellcome Trust
6 · The paper itself

Abstract

Gram-negative pathogens pose a significant threat due to their propensity for causing various infections, often coupled with formidable resistance to conventional antibiotic treatments. The development of antivirulence (AV) compounds emerges as a promising alternative strategy by disrupting virulence mechanisms rather than targeting bacterial viability. Aurodox has exhibited promising AV properties in previous studies by blocking the expression and function of the LEE-encoded type 3 secretion system (T3SS) in enterohaemorrhagic

Indexed as

Type III Secretion SystemsAnimalsAnti-Bacterial AgentsBacterial ProteinsGene Expression Regulation, BacterialGram-Negative BacteriaHumansMiceRAW 264.7 CellsSalmonella typhimuriumYersinia pseudotuberculosisAnti-Bacterial AgentsBacterial ProteinsType III Secretion Systemsaurodoxinfectionpolyketidetype 3 secretion systemvirulence

Identifiers

PMID39591989
PMCPMC11597412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.